- Intermittent treatment of ER+ BC with exemestane: Translational research
- Deletion of cyclooxygenase-2 in mouse mammary epithelial cells delays bc onset
- MiR-21 upregulation in breast cancer cells leads to PTEN loss and Herceptin resistanc
- Heat shock protein 90 inhibitors: New mode of therapy to overcome AI resistance
- Molecular basis of correlation between HER2+ and sensitivity to anthracyclines
- Building an accelerated path to tailored adjuvant cancer therapy
- Hypoxia regulates the breast cancer stem/progenitor cell population
- Obese mice that lose weight retain higher bc risk via mTOR pathway
- Curcumin analogues are cytotoxic towards ER- BC lines
- High expression of CXCL13 was associated with lower risk for relapse in Her2+ BC
- Activation of mTOR in obesity persists after weight loss
- 14-3-3zeta cooperates with ErbB2 in DCIS to invasive bc progression
- Copy number variation in low- and high-grade breast tumors
- Alternate mechanisms of PI3K pathway activation among subtypes of DCIS
- Expression patterns of the ERBB2 gene and associations with breast risk and survival
- Paradoxical actions of a c-Src inhibitor on long-term ER deprived cells
- Proteomics-based characterization of pathways involved in tamoxifen resistance
- M1 is a candidate proteasome activator drug in breast cancer that down-regulates Her2
- Newly designed nanobioconjugate for tx of Her2+ bc
- Aromatase expression promotes breast cancer tumorigenesis and bone metastasis
- Gene expression profiling in circulating cells (CTCs) a tool for early mets detection
- Circadian disruption and breast carcinogenesis
- Salivary biomarkers for breast cancer detection
- Gene expression profiling of hormone-regulating pathways
- Autophagy inhibition in endocrine resistant human breast cancer cell lines
- Urine biomarkers outperform serum biomarkers in the diagnosis of various human cancer
- Mammotrophic hormone score and risk of postmenopausal breast cancer
- Metformin enhances tumor regression and reduces tumor burden in mice
- FOXO1A is a target for HER2 overexpressing breast tumors
- Temporal changes of gene expression in bc cells during adaptation to ER deprivation
- Cyclin E amplification, a novel mechanism of resistance to trastuzumab in HER2+ bc
- Potential of PET imaging to predict the response to anti-HER2 therapy in breast cance
- Molecular markers for breast carcinogenesis models induced by environment & ER
- Plasma coenzyme Q10 levels and postmenopausal breast cancer risk
- Breast carcinoma DNA methylation profiles associated w/tumor size, alcohol & folate
- 2010 ASCO Abstracts
- June 2010: Updates from the 2010 ASCO Annual Meeting
- Treatment by subtype: a neoadjuvant study
- Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer
- Correlation of molecular and clinically distinct phenotypes in HER2+ ER+ BC
- Statistics from Peru for DFS and OS in Her2+ & ER+/- BC
- What ASCO Can Tell You About Biotechs
- ASCO: Leptin & High BMI May Reduce Her2+ Survival
- Ovarian suppression + endocrine therapy + zoledronic acid in premeno bc patients
- CK-19 mRNA-positive CTCs and Herceptin treatment
- Beta-blockers and ACE inhibitors in the prevention of trastuzumab-related cardiotoxic
- Dose-dependent interaction between tamoxifen and antidepressants on patient complianc
- Gene signature of metformin actions on primary breast cancer
- Association of gene copy number alterations with prognostic subtypes
- For T1a,b,N0M0 Her2+ patients not treated with chemo or Herceptin, age at dx importan
- Cause-specific and all-cause mortality of HER2-positive, node-negative, T1a & T1b bc
- Good news for triple positive (ER+/PR+/Her2+) bc
- HER2+ gene expression signature specific for trastuzumab resistance and poor prognosi
- Tykerb treatment for DCIS - study
- False-negative HER2 tests with appropriate positive controls
- Should liver metastases of breast cancer be biopsied to improve treatment choice?
- Discordance in hormone receptor status in breast cancer during tumor progression
- Biomarker changes associated with the development of resistance to AIs
- Early detection of recurrent breast cancer using metabolite profiling
- Safety and efficacy of low-dose metronomic chemotherapy with capecitabine
- Survival benefit of neck dissection for patients w/bc w/supraclavicurlar LN mets
- Circulating tumor cells (CTCs) and association with survival in molecular subtypes
- Impact of BMI on clinical outcome of HER2-positive breast cancer
- Method of detection of DCIS to predict HER2 overexpression
- A couple ASCO 2010 related links
- Is age an independent predictor of survival and time to recurrence in breast cancer?
- Association of phosphorylated-HER2 with relapse in patients
- Genomic profile of screen- and symptom-detected breast cancers and association w/ DFS
- In situ carcinoma (ISC) accompanying small (≤ 1 cm) invasive breast carcinoma (IBC)
- Is microcalcification on mammography relrelated to bone metastasis & bad prognosis?
- Molecular predictive factors of response to taxanes (T) and anthracyclines (A) in bc
- Long-term outcome of node-negative early breast cancer patients
- Breast cancer at the extremes of age: Predicting recurrence and mortality
- Can whole-brain irradiation (WBRT) be replaced by radiosurgery?
- Survival after supraclavicular recurrence of breast cancer
- Correlation between diabetes and ER/HER2 status in African Americans
- Subcutaneous testosterone-anastrozole implant therapy in breast cancer survivors
- Estrogen receptor positivity in normal breast epithelium from women with breast cance
- A phase I study to assess the safety, tolerability, and PK of ARRY-380, an oral HER2
- Evaluation of trastuzumab without chemotherapy as a postoperative adjuvant therapy
- The prognostic and predictive impact of BMI on clinical outcome of HER2-positive bc
- Is it safe to use transtuzumab for the treatment of breast cancer during pregnancy?
- Adjuvant trastuzumab therapy in tumors smaller than 1 cm
- The role of autophagy inhibition as a neoadjuvant therapy for DCIS
- Colon cancer risk
- FIRST study: Arimdex vs. Fulvestrant for Advanced BC
- CYP2D6 metabolism unrelated to Tamoxifen benefit
- Obesity at Dx associated with worse outcomes in HR+ BC
- Impact of BMI on endocrine tx in postmeno HR+ BC
- High baseline inflammatory signature results in lower response to AI's
- Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients
- BC Stem Cells survive Herceptin by downregulation of Her2
- Molecular Biomarkers for Resistance to Trastuzumab
- Tamoxifen, Flaxseed and Tumor Growth
- Omega-3 Fatty Acids for Chemoprevention
- Protective Effect of Dietary Intervention limited to high baseline Testosterone
- Chinese Herb Fructus Cornii prevents ER+ BC in the lab
- Safety of High Dose Vitamin D in pre-meno women
- Short-term exposure to pregnancy ER levels alters bc pathway development
- Short-term exposure to pregnancy level ER delays Her2+ tumor development
- Retesting Her2 status in metastatic patients cost effective and relevant
- No anti-tumor effects seen in adding Zolendraic acid to chemo
- Response to neoadjuvant chemo + Herceptin predicts survival
- Neoadjuvant trial of Concurrent Trastuzumab and Paclitaxel without Anthracycline
- Phase II trial of 4 drug combination for early Her2+ bc
- TN and Her2 bc more chemo sensitive but have higher rate of brain mets
- Her2+ patients Retain an Immunological Proficiency Compromised in Her2- cases
- Brain Met outcomes for Her2+ patients enrolled in LEAP
- Multi-Modality tx improves brain met survival
- Her2+ Correlates to Coexisting Invasion in DCIS
- Online Conference San Antonio Breast Cancer Symposium
- Herceptin + Pertuzumab active in Her2+ bc w/o chemo - NeoSphere study
- Discordance in Hormone Receptor and HER2 Status in BC during Tumor Progression
- Lab Findings: T-DM1 + PK13 inhibitor shows promise for Her2+ bc
- Lab Findings: Tykerb + Insulin/Insulin-like growth factor receptor for ER resistance
- Tykerb + Fulvestrant not useful in Her2+ ER+ metastatic pts. tx w/AI
- Discordant Pet scans (ER & Gloucose) predicts ER insensitivity in Her2+ Stage IV pts
- Her2+ BC account for large portion of Mammographic Failure to detect
- Ki67 Discriminates Luminal A & B BC better than Her2 status
- Study sugguests ER+ P13K activated tumors have strong Herceptin response
- Anti-Herceptin antibodies associated with longer PFS in Herceptin tx pts
- Circadian Clock Genes predict neoadj chemo response
- How Common Is Sexual Dysfunction among Women with Early Stage Breast Cancer?
- Factors Associated with Job Resumption after Primary Breast Cancer Treatment
- Metronomic Chemotherapy Inhibits Tumor Growth and Metastases Development in mice
- Phase II Trial Administering a HER2/neu-Derived Peptide vaccine w/Herceptin
- In Lab: Curcumin active against Her2 and may overcome Herceptin Resistance
- Using Serum Her2 levels to monitor response to neoadj chemo
- Influence of Body Mass Index on Presence of Disseminated Tumor Cells
- Androgen Receptor Expression in BC related to outcomes
- PR- bc patients have poorer outcomes when tx with SERMs
- Consistent Prognostic Impact of HER2 Status Over Time
- Early Detection of Recurrent Breast Cancer Using Metabolite Profiling
- Aspirin Use and the Risk of Breast Cancer
- LACE Study: Vitamin use and bc outcomes
- Increased Rate of HER2-Positive Breast Cancers among Women w/Germline TP53 Mutations
- Study of the best sequence for administration of Tykerb and AI's
- Efficacy and Safety of Neratinib (HKI-272) in Combination with Paclitaxel
- Responses to Subsequent Anti-HER2 Therapy after Treatment with T-DM1
- In the Lab: Development of a Her2 targeted anthracycline
- Can Resistance to Trastuzumab Be Reversed by Endocrine Therapy?
- Tumor Remissions under Trastuzumab Therapy
- Drug Development – Targeting HER2 beyond Trastuzumab
- Sentinel Node Trial: outcomes for micro and macro node mets
- Competing Causes of Mortality vs. Breast Cancer Mortality
- Weight loss in high risk postmeno women alters serum biomarkers assc w/bc
- BMI related to effectiveness of extended AI therapy
- Hormone-Receptor Expression and Activity of Trastuzumab-Based Therapy
- Lapatinib Resistance Confers Cross-Resistance to Microtubule Inhibitors
- Heat Shock Protein 90 Inhibitors: New Targeted Therapy To Overcome AI Resistance
- Plasticity of the ER and HER2 Signaling Networks
- Study: Higher BMI predicts poor neoadj response among Her2+
- Fat cells regulate bc functions differently in lean and obese women
- False Positive HER-2 Testing by Fluorescence In Situ Hybridization
- Correlation of Oncotype Dx Recurrence Score and Luminal Subtypes of Breast Cancer
- HERA subset analysis: effect of age on Her2+ outcomes
- Increase of Coronary Artery Stenosis after Radiation for Breast Cancer
- Truncated ERBB2 Receptors: Diagnostic and Therapeutic Targets
- BreastCancerTrials.org: Nationwide Clinical Trial Matching Service
- Evaluating the Efficacy of chemo in postmeno ER+ pts
- ER Positive Screen Detected Breast Cancers Do Not Require Chemotherapy
- Cognitive Effects of Endocrine Therapy in Patients with Breast Cancer
- Investigating Early Features of Aromatase Inhibitor-Induced Arthralgia
- Concurrent vs. Sequential Administration of Adjuvant Trastuzumab
- Symptom Burden of patients receiving chemo + Herceptin improves when chemo stops
- Patterns of Relapse According to Subtypes in LNN BC
- Impact of Adjuvant Trastuzumab on Local Regional Recurrence
- Seroma Formation Is Associated with Lymphedema-Related Symptoms
- Could We Reduce the Number of Exams in the Follow-Up of Breast Cancer Survivors
- Next-Generation Transcriptome Sequencing of the Normal Breast
- Resolving the problem of intra tumoral Her2 heterogeneity
- Relationship between Vitamin D Deficiency and Breast Cancer Histology
- Insulin Resistance, Diabetes Mellitus and Breast Cancer and moderate exercise
- Oral Contraceptive Use and Overall Breast Disease Risk
- Dual Estrogen Effects on Breast Cancer
- Use of Selective COX-2 Inhibitors and Breast Cancer Recurrence
- Phase II Multicenter Study of Docetaxel and Bevacizumab (Bev) +/- Trastuzumab for MBC
- Evidence for Treatment of Metastatic Breast Cancer beyond 2nd Line
- Phase II study of T-DM1 + PI3K Inhibitor
- Phase I study of a Her2/Her3 heterodimer drug
- Targeting Her2: Beyond Trastuzumab
- c4yw
- 'Aging in the know' from Health In Aging
- Targeting Her2 - Podcasts from SABCS
- Metformin potentiates the efficacy of radiotherapy
- Combating trastuzumab resistance by targeting Src
- Social isolation stress-induced obesity increases mammary cancer risk
- Research on reversing Herceptin resistance
- Biomarkers of Response to Herceptin + Chemo
- Endoxifen exhibits anti-tumor activity in Her2+, tamox resistant tumors in lab
- Delphinidin dietary anthocyanidin modulates EGFR/HER-2 signaling pathway in bc cells
- Short-term pregnancy levels of estradiol delays Her-2+ mammary tumor development
- Signaling networks potentially involved in breast cancer metastasis to the brain
- Heat shock protein vaccines for immunotherapy of Her-2/neu positive breast cancers
- Autophagy and HER2 interaction in mammary tumorigenesis
- Entosis: Adhesion, autophagy, and murder
- Exposure to gefitinib during premalignant risk window/lifelong protection to MMTV mic
- Effects of aerobic training to improve cardiovascular function after chemo
- Epigenetic portraits of human breast cancers
- A difference of HER-2 amplification index between luminal B and HER2 enriched subgrou
- HER2/neu positive receptor status is associated with a low DNA repair capacity in bc
- Amplification of tumor immunity with cryoablation
- Curcumin suppresses the expression of HER-2 gene
- Sustained release curcumin microparticles show promise as chemopreventive against HER
- Night work and breast cancer risk: CECILE study
- Regulation of Her-2 in long-term letrozole resistant cells by HSP-90
- Overcoming trastuzumab resistance with the irreversible Pan-HER inhibitor neratinib
- In vitro cell and in vivo animal studies of the demethylating agent in treating HER2+
- Serotonin signaling plays a role in regulation of autophagy in breast cancer cells
- Lab Model of Lapatinib Resistance
- Enhancement of trastuzumab selectivity via cyclic complex formation
- PTEN deletion: An underlying mechanism for PTEN loss in breast cancer
- Effects of bc protection of pregnancy on Her2- vs Her2+ bc
- ASCO 2011 abstracts available
- Oncotype returns high false negative of Her2 results
- Good results for small tumors tx with Herceptin
- Protection of adjuvant trastuzumab in sites of early relapses
- Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer
- Long-term responders to trastuzumab
- Impact of a change of body mass index following adjuvant tx
- St. Gallen Endocrine classifications and recurrence
- New Directions in the Treatment of Patients With HER2-positive Breast Cancer
- ASCO 2011 from CURExtra
- 2011 ASCO Podcasts
- Upcoming conferences in Sweden
- Nov. 17 CancerConnect - CIM - Ask the expert
- SABC on Cure
- SABCS 2011 - videos +
- Novel Approaches to Breast Cancer Management in Low-Income Countries
- Adjuvant Therapy in Patients with a Borderline HER-2 Status
- The Cytotoxicity of Select Neutrophils in Cancer Patients
- Zoledronic Acid Reverses the Epithelial-Mesenchymal Transition
- Adipose Tissue in Breast Cancer: an Active Participant in Breast Cancer Progression
- T-DM1 and Pertuzumab as New Tools for HER2 Specific Antibody-Therapy
- Early decrease in CTC level = response to Tykerb & Capecetibine in Her2+ brain mets
- Changes in Gene Expression after One Dose of Trastuzumab
- Consistent High False Negative Rate of HER2 qRT-PCR of Oncotype DX®
- Huge Improvement in Relapse-Free Breast Cancer Survival over the Last 25 Years
- Obesity, Adjuvant Therapy, and Survival Outcomes in Early-Stage Breast Cancer
- Age and Survival in Women with Early Stage BC: An Analysis Controlling for subtype
- Pattern of Cardiac Monitoring and Risk of Trastuzumab Associated-Cardiac Dysfunction
- Aspirin Exposure and Nodal Status at Diagnosis in Women with Stage I-III Breast Cance
- Treatment Patterns and Clinical Outcomes in Elderly Patients with HER2+ MBC
- Assessment of the impact of ineffective treatments on metastatic breast cancer
- HDL-Cholesterol and Low-Penetrance Gene CYP17 rs2486758 Influence Daily Estrogen Leve
- Prevalence of Germline TP53 Mutations in Young Women with HER2-Positive Breast Cancer
- Fetal Microchimerism and In Situ Breast Cancer
- Pregnancy during and Following Adjuvant Trastuzumab
- Combined Targeting of the PI3K Pathway and HER2 Overcomes Trastuzumab Resistance
- Complete Pathological Response of DCIS after Treatment with Neoadjuvant Herceptin